17 apr: Europa/luk: Finanssektoren trak kraftigt op
18 apr: USA/aktier: Største stigninger i en måned
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
24 apr - 
Fredagens aktier: Storbanker sender Pandora i rekord ..
24 apr - 
Aktier/middag: Pandora smykker sig igen med rekord ..
24 apr - 
Novo: Astrazeneca-regnskab gøder jorden for stærkt Vict..
Relateret debat
24 apr - 
Mangler altid ekstra Novo til depotet. Kan ikke få nok
24 apr - 
Runder 400 når USD runder 7,10 DKK. Forbavser mig at No..
24 apr - 
Sjovt

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 apr
NOVO-B
Ja, grundlæggende har xo33, twitia m.fl. taget fejl gentagne gange, og ser ud til at fortsætte med a..
10
20 apr
NOVO-B
Ja, det er efterhånden sket mange gange i år, der loves bål og brand og alle de små investorer sælge..
4
23 apr
NOVO-B
Det gør den ikke, fordi jeg kun har fået købt 200, og har en målsætning om, at jeg skal have 400. De..
3
22 apr
NOVO-B
Jo men jeg supplerer altid på vej ned.   Jeg ved jo godt jeg indimellem tager fejl, derfor køber jeg..
3
20 apr
NOVO-B
Der er ikke noget med det, de har skrevet. Det er tidspunktet, den er gal med.   Jeg tror vi får en ..
3
24 apr
NOVO-B
For så bliver du glad og så får jeg mere tid med din kone :-).
2
21 apr
NOVO-B
Køb og gem væk. Køb og gem væk. Den 14-dobler igen de næste 10 år.... Cola og popcorn!
2
21 apr
NOVO-B
At du får den kurs for dine aktier som der er blevet budt pr. stk. Efter handlen er du ikke længere ..
2
21 apr
NOVO-B
Det historiske billede er, at for vi kan få en større korrektion, skal vi se en "slow down" i amerik..
2
20 apr
NOVO-B
Folk tror at aktier kun kan stige.   Men får et chok når de så falder 30-40 %    Men sådan er gamet ..
2

Carlsberg glæder sig over russisk kontrol-udskydelse

24-04-2015 15:54:28
Bryggerierne i Rusland, herunder Carlsberg, glæder sig over en beslutning fra myndighedernes side om at udskyde tidspunktet for, hvornår de skal tilslutte sig d..

DSV/Nykredit: Hæver anbefaling til "outperform"

24-04-2015 12:52:42
Nykredit Markets hæver anbefalingen af aktien i DSV til "outperform" fra "underperform", efter at aktien har klaret sig dårligere end det generelle marked de se..

Novo: Astrazeneca-regnskab gøder jorden for stærkt Victoza-salg

24-04-2015 09:59:32
Svensk-britiske Astrazeneca har fremlagt sit regnskab for første kvartal, der viser, at salget af nye diabetespræparater er vokset 47 pct. år til år, og selvom ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Novo: Astrazeneca-regnskab gøder jorden for stærkt Victoza-salg
2
Aktier/tendens: Amerikanske regnskaber peger på positiv åbning
3
Novozymes: Finanshuse reagerer uens på regnskab
4
Novozymes: Kvartalsregnskab får finanshuse til at se på aktien
5
Kinesisk Vestas-konkurrent i kraftig fremgang

Relaterede aktiekurser

Novo Nordisk B A/S 390,30 1,3% Stigning i aktiekurs
Novo-Nordisk A/S 56,65 0,8% Stigning i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. april 2015 08:34:12
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150423.1 - EUROWEB5 - 2015-04-25 08:34:12 - 2015-04-25 08:34:12 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x